Alan Korman

Alan Korman

UNVERIFIED PROFILE

Are you Alan Korman?   Register this Author

Register author
Alan Korman

Alan Korman

Publications by authors named "Alan Korman"

Are you Alan Korman?   Register this Author

75Publications

4456Reads

37Profile Views

Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV Cancers.

Cancer Immunol Res 2020 Jan 26;8(1):131-145. Epub 2019 Nov 26.

Swiss Institute for Experimental Cancer Research, School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-19-0315DOI Listing
January 2020

New epitopes in ovalbumin provide insights for cancer neoepitopes.

JCI Insight 2019 Mar 14;5. Epub 2019 Mar 14.

Department of Immunology, University of Connecticut School of Medicine, Farmington, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.127882DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538383PMC
March 2019

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients.

PLoS One 2018 7;13(6):e0198158. Epub 2018 Jun 7.

Translational Science and Clinical Oncology, Regeneron Pharmaceuticals, Tarrytown, New York, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0198158PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991705PMC
January 2019

Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model.

Prostate Cancer Prostatic Dis 2018 04 4;21(1):113-125. Epub 2017 Dec 4.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-017-0013-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897134PMC
April 2018

Conditioned media from the renal cell carcinoma cell line 786.O drives human blood monocytes to a monocytic myeloid-derived suppressor cell phenotype.

Cell Immunol 2018 01 31;323:49-58. Epub 2017 Oct 31.

ZymoGenetics, a Bristol-Myers Squibb Company, 1201 Eastlake Ave. East, Seattle, WA 98102, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cellimm.2017.10.014DOI Listing
January 2018

CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8 T Cell-Relevant Genes.

Cancer Immunol Res 2018 01 13;6(1):69-78. Epub 2017 Nov 13.

Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-17-0159DOI Listing
January 2018

Masterful Antibodies: Checkpoint Blockade.

Cancer Immunol Res 2017 04;5(4):275-281

Bristol-Myers Squibb, Biologics Discovery California, Redwood City, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-17-0057DOI Listing
April 2017

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.

Cancer Immunol Res 2017 02 10;5(2):106-117. Epub 2017 Jan 10.

Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-16-0391DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510474PMC
February 2017

Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor.

Cancer Res 2016 11 9;76(21):6266-6277. Epub 2016 Sep 9.

Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-16-2141DOI Listing
November 2016

In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.

Cancer Res 2016 07 6;76(13):3929-41. Epub 2016 May 6.

Department of Human Oncology, University of Wisconsin, Madison, Wisconsin. Department of Pediatrics, University of Wisconsin, Madison, Wisconsin. Department of Genetics, University of Wisconsin, Madison, Wisconsin.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-2644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930687PMC
July 2016

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.

Cancer Cell 2016 06 2;29(6):820-831. Epub 2016 Jun 2.

Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 1230 York Avenue, New York, NY 10021-6399, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.05.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975533PMC
June 2016

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.

Cancer Cell 2015 Sep;28(3):285-95

Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2015.08.004DOI Listing
September 2015

Evolving synergistic combinations of targeted immunotherapies to combat cancer.

Nat Rev Cancer 2015 Aug;15(8):457-72

The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc3973DOI Listing
August 2015

The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience.

Pharmacol Ther 2015 Apr 1;148:132-53. Epub 2014 Dec 1.

Bristol-Myers Squibb, Research and Development Division, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2014.11.017DOI Listing
April 2015

Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more.

Oncoimmunology 2012 Oct;1(7):1172-1174

Department of Immunology; St. Jude Children`s Research Hospital; Memphis, TN USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.20593DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494635PMC
October 2012

B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.

J Immunol 2012 Jul 25;189(1):39-49. Epub 2012 May 25.

Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, 6525 GA Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1102807DOI Listing
July 2012

Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.

J Transl Med 2012 May 28;10:108. Epub 2012 May 28.

Centro de Investigacion Medica Aplicada, Universidad de Navarra, Avda Pio XII, 55, 31008 Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-5876-10-108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404934PMC
May 2012

Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3.

J Immunol 2011 Oct 26;187(7):3493-8. Epub 2011 Aug 26.

Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1100714DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178660PMC
October 2011

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

Semin Oncol 2010 Oct;37(5):533-46

Global Clinical Research, Oncology, Bristol-Myers Squibb Co, Wallingford, CT 06492, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2010.09.015DOI Listing
October 2010

PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.

Int Immunol 2009 Sep 3;21(9):1065-77. Epub 2009 Aug 3.

Donald A Adam Comprehensive Melanoma Research Center, Department of Immunology and Immunotherapy, Moffitt Cancer Center, 12902 Magnolia Drive, SRB-24324, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/intimm/dxp072DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731790PMC
September 2009

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.

J Exp Med 2009 Aug 6;206(8):1717-25. Epub 2009 Jul 6.

Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://www.jem.org/lookup/doi/10.1084/jem.20082492
Publisher Site
http://dx.doi.org/10.1084/jem.20082492DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722174PMC
August 2009

Checkpoint blockade in cancer immunotherapy.

Adv Immunol 2006 ;90:297-339

Medarex Inc., Milpitas, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0065-2776(06)90008-XDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1951510PMC
May 2009

Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.

Int Immunol 2007 Oct;19(10):1223-34

Department of Medicine, University of Southern California, 1441 Eastlake Avenue, Room 6428, Los Angeles, CA 90033, USA.

View Article

Download full-text PDF

Source
https://academic.oup.com/intimm/article-lookup/doi/10.1093/i
Publisher Site
http://dx.doi.org/10.1093/intimm/dxm091DOI Listing
October 2007

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.

Curr Opin Immunol 2006 Apr 7;18(2):206-13. Epub 2006 Feb 7.

Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coi.2006.01.011DOI Listing
April 2006

Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.

Curr Opin Investig Drugs 2005 Jun;6(6):582-91

Medarex Inc, 521 Cottonwood Drive, Milpitas, CA 95035, USA.

View Article

Download full-text PDF

Source
June 2005

Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques.

J Immunol 2003 Dec;171(11):6251-9

Department of Preclinical Development, Medarex, Bloomsbury, NJ 08804, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.171.11.6251DOI Listing
December 2003